Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., No. 17-2557 (Fed. Cir. Nov. 20, 2018)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Tris Pharma, Inc. (Tris) holds the approved New Drug Application for Quillivant XR ®, an extended release methylphenidate (MPH) formulation for the treatment of Attention Deficit Hyperactive Disorder (ADHD). When Actavis Laboratories, Inc. (Actavis) submitted an Abbr e- viated New Dr ug Application (ANDA) to the U.S. Food & Drug Administration (FDA) seeking approval to market generic versions of Quillivant XR ®, Tris sued Actavis for infringement of U.S. Patent Nos.